Renewable Energy Stock Alert: Solar Wind Energy Tower, Inc. (SWET) Extends Rights to Develop Energy Downdraft Towers in Rajasthan, India

ANNAPOLIS, MD - November 12, 2013 (Investorideas.com renewable energy stocks newswire) Solar Wind Energy Tower, Inc. (OTCQB: SWET) (the "Company"), the inventor of a large Solar Wind Downdraft Tower structure capable of producing abundant, inexpensive electricity, announced today that it has entered into a Memorandum of Understanding with Monsoon Global Group, LLC, which grants Monsoon Global a "Exclusivity Period" for rights to license trade secrets, patents, and knowledge from Solar Wind Energy. During the "Exclusivity Period" Monsoon has the exclusive right to "hold itself out in Rajasthan, India" to enter into long term "Definitive Agreement" with Solar Wind Energy to use the rights to develop Solar Wind Energy Downdraft Towers in Rajasthan, India.

Under the "Definitive Agreement " Solar Wind Energy will provide technical support and personnel to advise and assist Monsoon Global Group in project development, design, procurement, construction and the operation of a Tower Facility. Solar Wind Energy will also assist Monsoon Global Group with the technical and feasibility studies as well as presentations necessary for proposals to various Government of India Ministries and potential project participants. The Memorandum of Understanding outlines terms of the license fee for the territory of Rajasthan as well as specific royalties and fees for each Tower Facility within the territory.
Ronald Pickett, CEO, Solar Wind Energy Tower, Inc. commented: "We are pleased to have formed this relationship with Monsoon Global. We have worked diligently for over three years assembling the team, techniques, and knowhow to enable this clean alternative energy solution to be brought to market. Our business plan has always been to enable developers to materialize projects across the globe where weather conditions are most suitable. Rajasthan, India has one of these 'most suitable' environments to host our Towers and India certainly needs the power."
About Solar Wind Energy, Inc.
Solar Wind Energy, Inc. ("Solar Wind Energy"), a wholly owned subsidiary of Solar Wind Energy Tower, Inc., was established to utilize proven and validated scientific principles, combining them with state of the art construction systems to enable the development and commercialization of large Solar Wind Downdraft Tower structures that produce abundant, inexpensive electricity. Our Company's core objective and focus is to become a leading enabler of clean, efficient green energy to the world communities, at a reasonable cost, without the destructive residuals of fossil fuels, while continuing to generate innovative technological solutions for tomorrow's electrical power needs. The Company intends to establish partnerships at home and abroad to propagate Tower Projects and meet the increasing global demand for electricity. The Company does not intend to own the projects. The business plan includes receiving license fees for territories, development fees during construction, and recurring royalty fees based on the actual kilowatt hours produced by the Tower. Solar Wind Energy has assembled a team of experienced business professionals, engineering and scientific consultants with the proven ability to bring this solution to market. Solar Wind Energy has filed and been issued patents that the Company believes will further enhance this potentially revolutionary technology. Solar Wind Energy, Inc., based in Annapolis, MD, is traded on the OTCQB under the symbol 'SWET'. For more information visit www.solarwindenergytower.com
Innovative Renewable Hybrid Solar / Wind Energy Technology
We view ourselves as a hybrid solar/wind technology, reflected in the name, Solar Wind Energy Tower, Inc. The simplicity of our solution is comprised of harnessing the natural power of a downdraft created within the confines of our Solar Wind Downdraft Tower structure, a hollow cylinder reaching skyward into the hot, dry atmosphere heated by the solar rays of the sun. The water introduced by the injection system near the top of the Tower evaporates and is absorbed by the hot, dry air. The air becomes cooler, denser and heavier than the outside warmer air and falls through the cylinder at speeds up to and in excess of 50 mph and is diverted into wind tunnels surrounding the base of the Tower where turbines inside the tunnels power generators to produce electricity.
Abundant, Clean, Affordable Electricity Production
The Company has successfully managed to economize the Tower, reducing capital costs and improving projected financial performance. This development was made possible by utilizing our recently announced software which can calculate and predict energy production by our Solar Wind Downdraft Towers given local weather data. By feeding the weather data into the program, the Tower's height and diameter can be adjusted along with the amount of water added as fuel to create a desired amount of energy. The outcome dictates the optimum size of the Tower's height and width.
Under the most recent design specifications, the first San Luis Tower has a design capacity on an hourly basis, of up to 1,250 megawatt hours, gross. Due to lower capacities during winter days, the average hourly output per day for sale to the grid for the entire year is approximately 435 megawatt hours.
Cautionary Note Regarding Forward-Looking Statements
Statements included in this release may constitute "forward-looking statements". Actual results may differ materially from those projected in forward-looking statements. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the Company's ability to obtain new contracts and accurately estimate revenues, if any, due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Company's financial results, can be found in the Company's various filings with the Securities and Exchange Commission (SEC).
Contact:
Solar Wind Energy, Inc.
1997 Annapolis Exchange Parkway
Suite 300
Annapolis, Maryland 21401
Phone: 410-972-4713
E-mail: Info@swetower.com
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense renewable energy, food and beverage stocks and others.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for our news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and use our 14 online stock directories to research stocks - waters stocks, renewable energy, tech, mobile, mining stocks and more… http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: Investorideas.com was paid five hundred dollars for this news release distribution
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com

Biometric Stock Alert: Synaptics (SYNA) Closes Acquisition of Validity Sensors

SAN JOSE, Calif. - November 11, 2013 (Investorideas.com Newswire) Synaptics Inc. (SYNA), a leader in human interface solutions, announced Friday it has completed its acquisition of Validity Sensors, Inc. ("Validity") on November 7, 2013. Expansion into the fingerprint identification market, with the acquisition of a world class Validity team that delivers industry-leading solutions, is an integral part of Synaptics' growth strategy as it immediately expands the depth and breadth of solutions available to its global partners.

As consumer demand for fingerprint ID integration into intuitive smart devices continues to grow, OEMs are looking to differentiate their products with the innovative solutions Synaptics' partners have come to expect. With the addition of Validity's secure, high-performance and cost-effective solutions to Synaptics' core family of industry-leading ClearPad® and TouchPad™ solutions, partners will have access to the industry's broadest portfolio of leading-edge human interface solutions for smartphones, tablets, and notebook PCs.
"We have received overwhelmingly positive customer feedback on the strength of the combined organizations and the opportunities that lie ahead for Synaptics," said Rick Bergman, Synaptics CEO and president. "As the leading human interface solution provider we are well positioned both, competitively and strategically, to exceed the needs of our global partners."
For up-to-the-minute Synaptics news, follow @SynaCorp on Twitter or visit our blog at blog.synaptics.com.
For more information on Synaptics' products and solutions please visit www.synaptics.com.
About Synaptics
As a leading developer of human interface solutions which enhance the user experience, Synaptics provides the broadest solutions portfolio in the industry. The ClearPad family supports touchscreen solutions for devices ranging from entry-level mobile phones to flagship premium smartphones, tablets and notebook PCs. The TouchPad family, including ClickPad™ and ForcePad®, is integrated into the majority of today's notebook PCs. Synaptics LiveFlex® fingerprint sensor technology enables authentication, mobile payments, and touch-based navigation for smartphones, tablets, and notebook PCS. Synaptics' wide portfolio also includes ThinTouch® supporting thin and light keyboard solutions, as well as key technologies for next generation touch-enabled video and display applications. (SYNA) www.synaptics.com
Forward-Looking Statements
This press release contains "forward-looking" statements about Synaptics, as that term is defined under the federal securities laws. Synaptics intends such forward-looking statements to be subject to the safe harbor created by those laws. Such forward-looking statements include, but are not limited to, statements regarding Synaptics' expectations of the depth and breadth of its solutions; Synaptics' expectations regarding the demand for fingerprint ID integration; OEMs' desire to differentiate their products with Synaptics' solutions; Synaptics' belief that its solutions will provide its partners with access to the industry's broadest portfolio of leading-edge human interface solutions for smartphones, tablets, and notebook PCs; and Synaptics' belief that it is well positioned both competitively and strategically to exceed the needs of its global partners. Synaptics cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained herein. Such factors include, but are not limited to, (a) demand for Synaptics' and Validity's products, (b) market demand for OEMs' products using Synaptics' or Validity's solutions, (c) changing market demand trends in the markets Synaptics or Validity serves, (d) the success of Synaptics' and Validity's customers' products that utilize Synaptics' or Validity's product solutions, (e) the development and launch cycles of Synaptics' and Validity's customers' products, (f) market pressures on selling prices, (g) the market acceptance of Synaptics' and Validity's product solutions compared with competitors' solutions, (h) general economic conditions, including consumer confidence and demand, and (i) other risks as identified from time to time in Synaptics' SEC reports, including Quarterly Reports on Form 10-Q and the Annual Report on Form 10-K for the fiscal year ended June 30, 2013. All forward-looking statements are based on information available to Synaptics on the date hereof, and Synaptics assumes no obligation to update such statements.
Synaptics and the Synaptics logo are trademarks of Synaptics in the United States and/or other countries. All other marks are the property of their respective owners.
Previous Investorideas interview with SYNA
Synaptics (SYNA) Biometrics Acquisition Adds Momentum to Sector
Investorideas.com talked to leading analysts and experts at Frost & Sullivan, Goode Intelligence and NXT-ID Inc (OTCQB: NXTD) to gain insight into the significance of the deal. Additionally, we asked Alfred Woo, product-marketing manager at Synaptics to discuss the recent acquisition.
http://finance.yahoo.com/news/synaptics-syna-biometrics-acquisition-adds-123000997.html

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) to Present at SeeThruEquity Investor Conference

SAN DIEGO - November 7, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), announced today that Company Chairman and CEO, Jim Joyce will present a corporate overview at the SeeThruEquity Investor Conference on November 12th at 10:30 am Eastern Standard Time (EST). Mr. Joyce's presentation will be webcast via the following link: http://wsw.com/webcast/seethru5/AEMD. The conference will be held at Convene Midtown East (730 Third Avenue), New York City. Additional details can be accessed online at: www.seethruequity.com

Aethlon is currently preparing to launch the first U.S. studies of Hemopurifier® therapy based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA) to initiate feasibility studies in Hepatitis C (HCV) infected individuals.
On the evening of November 12th, Mr. Joyce will also co-host a grand opening event for the Company's Exosome Sciences, Inc. (ESI) subsidiary at 6:30pm EST. Individuals that wish to attend the event should RSVP by email to Chris Wetzel (ESI Director of Operations) by the end of the business day on Friday November 8th. Chris's email address is: cwetzel@exosomesciences.com. The event will be held at the recently established ESI lab located within the Princeton Research Center. The address is 11 Deer Park Drive, Suite 103, Monmouth Junction, NJ 08852. Directions can be accessed online at: www.princetoncorporateplaza.com/contact.html.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Mining Stock Alert: DNA Precious Metals, Inc. (OCTQB: DNAP) Acquires the Complete Geological Data Resource on the Historic Montauban Mine

MONTREAL - November 6, 2013 (Investorideas.com Mining stocks newswire) DNA Precious Metals, Inc. (DNAP) announces that the Company has closed an agreement to acquire the complete geological data resource on the Montauban Mine, in addition to its October 22, 2013 press released "Binding Agreement to acquire an undivided one hundred percent (100%) interest for all of the Montauban Mine Property located in Notre-Dame-de-Montauban, Quebec, Canada".

The geological data, dating from the start of production in 1914 to the last exploration in 2011, consists of over 1000 reports, drill logs, geological maps of near surface deposits, maps of underground mine workings, digital files and a Gemcom modeling of the mine. The acquisition fast tracks the timeline on Montauban and enables DNA to immediately commence a NI 43-101 compliant report on the Montauban Mine, which currently has a non compliant historic near surface resource of over 1M tons of 3.4 g/t Au and approximately 1 ounce per ton silver as well as significant underground potential from this past producer.
"We are excited about the acquisition of the data resource assets due to the potential of the historical mineral resources. Over 1Mt of resource have been identified with historical drilling on the Montaban Mine project, which given its location, geology and metallurgy, could generate value for our shareholders," commented Ronald Mann, President and Chief Executive Officer of DNA Precious Metals. "These assets came to the attention of DNA through our research as we continue to focus on the development of our flagship Montauban Mine Project in Quebec, Canada and as we target updating our current resource estimate to define a mineable resource to bring into production."
About DNA Precious Metals, Inc.
DNA Precious Metals, Inc. is focused on near term production of the Montauban tailings mine in the Province of Quebec, Canada with an aggressive search for economic production assets. The company trades on the OTCQB market in the United States under the stock symbol DNAP. For more information, please go to   www.DNAPreciousMetals.com .
On behalf of the Board
Ronald K. Mann, CEO
Forward Looking Disclaimer
This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at http://www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts' expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company's future stock price, its revenues or results of operations.
CONTACT INFORMATION
Ronald Mann, CEO
DNA Precious Metals Inc.
ronald.mann1@dnapreciousmetals.com
Twitter: www.twitter/dnametals
Facebook: www.facebook.com/dnametals
INVESTOR RELATIONS
Stuart T. Smith, CEO
SmallCapVoice.Com, Inc.
ssmith@smallcapvoice.com
Tel: +1-(512)-267-2430
Skype: SmallCapVoice.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Investorideas is compensated by DNAP for news and content publication and syndication ( October 2013 - five thousand for one month of news distribution on Investor ideas news wire ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Equity Research: NXT-ID (OTCQB:NXTD) Mobile-Bio Platform Enables M-Commerce

November 6, 2013 (Investorideas.com biometrics/ defense stocks newswire) SeekingAlpha.com: SoundView Technology Group issues equity research note - NXT-ID (OTCQB: NXTD) Mobile-Bio Platform Enables M-Commerce.

Technology is finally enabling bio-based security features on mobile devices that will overcome one of the final obstacles to truly mobile digital commerce. One company, NXT-ID (OTC:NXTD), has emerged as a newly public company with a set of technologies and an open platform that can be used across all these applications. Based on our analysis the next few quarters of adoption will drive a near-term intrinsic value of over $10/share and a much higher figure for 2014. This report goes into more detail concerning the technology, the market, and the company.
Device-level sensors, biometrics and embedded processing have arrived. With these advanced technologies, the wallet can be made more versatile, secure and powerful with modern technology built into it. This same approach will be found in a broad range of products from firearms to autos, which will only fire and run if the authorized owner is securely identified and in command. The IT companies have provided more security (multi-factor, out-of-band authentication) but these don't work well because they are neither simple nor obvious. It's now pretty easy to know that "you are you" given enough of the right sensor and biometric information combined with the right data and some local processing.
In the future, it is likely that we are not going to carry around little pieces of colored plastic to make payments; furthermore, we are not going to rely on simple alphanumeric passwords to access our devices and conduct transactions. Lest everyone think the smartphone will save the day, it has a few chronic weaknesses. Power is the most basic one. Consumers expect their keys and wallet to work all the time. Smartphones are not secure or private in the slightest, nor are they likely to become so for quite some time.
Full article http://seekingalpha.com
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms. NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Published at Investorieas.com
About www.InvestorIdeas.com: Big Ideas for global investors, InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors.
Research Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Frac Water Stock Alert: HII Technologies, Inc. (HIIT) Announces a Strategic Alliance With CRS Reprocessing Services

HOUSTON - November 5, 2013 (Investorideas.com Newswire) HII Technologies, Inc. (the "Company"), symbol HIIT (OTCBB/OTCQB: HIIT), an oilfield services company headquartered in Houston, Texas, with operations in Texas, Oklahoma, Ohio and West Virginia today announced it has entered into a strategic alliance agreement with CRS Reprocessing Services ("CRS"), a global fluids reprocessing management company that is headquartered in Louisville, Kentucky. The technology alliance was formed to broaden and enhance the services AES Water Solutions ("AES") provides in its water and fluids remediation business during onsite fracing operations.

Utilizing the proprietary technology and modular design of CRS's systems, AES will be able to provide drilling fluid reprocessing and top hole solids control to its customers' well site operations. AES anticipates this to elevate its existing service offering by efficiently maximizing the recovery of valuable materials while reducing the risks and costs associated with transporting such fluids to distant reprocessing sites. Additionally, the modular units permit AES to address the varying needs of its customers, while minimizing the footprint necessary to operate.
Mr. Brent Mulliniks, President of AES Water Solutions, stated, "The CRS Reprocessing alliance is strategic to our firm by enabling us to immediately provide additional remediation and reprocessing services onsite to our existing and future customers furthering AES' commitment to provide comprehensive water management services to our customers. The technologies offered by CRS will compliment AES' existing water transfer, flow-back and remediation services." Mr. Mulliniks also stated, "As a result of this alliance, we believe CRS' technologies will provide an advantage for AES in the Texas and Oklahoma markets where we operate while expanding revenues and attracting additional customers."
Scott Massie, CEO of CRS Reprocessing Services, stated, "AES' focus in the Texas and Oklahoma markets increases our technology's access to some of the most active oilfield plays in the domestic United States including the Eagle Ford, Permian, Granite Wash and Eaglebind plays. Our success is due to our great people who have built an excellent track record with our customers and partners. We look forward to applying these same principles in the AES relationship in these key markets — building value in both our companies."
About HII Technologies, Inc.
HII Technologies, Inc. is a Houston, Texas based oilfield services company with operations in Texas, Oklahoma, Ohio and West Virginia. The Company is positioned to take advantage of the significant anticipated growth in horizontal drilling and hydraulic fracturing within the United States' active shale and unconventional "tight oil" plays by deploying new oilfield related technologies to enhance the value of services it offers its customers. The Company's frac water supply services subsidiary does business as AES Water Solutions, its onsite oilfield contract safety consultancy does business as AES Safety Services, and its mobile oilfield power subsidiary does business as South Texas Power (STP). The holding company, HII Technologies' objective is to bring proven technologies to these operating divisions to build a long-term competitive advantage. Read more at www.HIITinc.com, www.AESwatersolutions.com and www.Oilfield-Generators.com.
About CRS Reprocessing, LLC.
CRS is a global provider in fluid reprocessing management, offering people, technology and services to efficiently handle industrial fluids for a variety of industries. With more than 30 years of expertise and operations in the U.S., Europe and Asia, the company provides custom-built, on-site reprocessing and mobile facilities that economically transform used fluids back to customer-specified performance levels, allowing high-yield waste recovery and lower unit costs. CRS' leadership in the fluid reprocessing market includes proprietary recycling processes.
The company's private-equity partners have a combined portfolio value in excess of $1 billion, giving it the capital resources to expand operations and deliver engineered reprocessing solutions worldwide.
More information about CRS can be found online at www.crs-reprocessing.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements as to matters that are not of historic fact are forward-looking statements. These forward-looking statements are based on HII's current expectations, estimates and projections about HII, its industry, its management's beliefs and certain assumptions made by management, and include statements regarding estimated capital expenditures, future operational and activity expectations, international growth, and anticipated financial performance in 2013. No assurance can be given that such expectations, estimates or projections will prove to have been correct. Whenever possible, these "forward-looking statements" are identified by words such as "expects," "believes," "anticipates" and similar phrases.
Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict, including, but not limited to: risks that HII will be unable to achieve its financial, capital expenditure and operational projections, including quarterly and annual projections of revenue and/or operating income and risks that HII's expectations regarding future activity levels, customer demand, and pricing stability may not materialize (whether for HII as a whole or for geographic regions and/or business segments individually); risks that fundamentals in the U.S. oil and gas markets may not yield anticipated future growth in HII's businesses, or could further deteriorate or worsen from the recent market declines, and/or that HII could experience further unexpected declines in activity and demand for its hydraulic frac related water transfer business, its safety consultancy business or its generator and related equipment rental service businesses; risks relating to HII's ability to implement technological developments and enhancements; risks relating to compliance with environmental, health and safety laws and regulations, as well as actions by governmental and regulatory authorities; risks that HII may be unable to achieve the benefits expected from acquisition and disposition transactions, and risks associated with integration of the acquired operations into HII's operations; risks, in responding to changing or declining market conditions, that HII may not be able to reduce, and could even experience increases in, the costs of labor, fuel, equipment and supplies employed and used in HII's businesses; risks relating to changes in the demand for or the price of oil and natural gas; risks that HII may not be able to execute its capital expenditure program and/or that any such capital expenditure investments, if made, will not generate adequate returns; and other risks affecting HII's ability to maintain or improve operations, including its ability to maintain prices for services under market pricing pressures, weather risks, and the impact of potential increases in general and administrative expenses.
Because such statements involve risks and uncertainties, many of which are outside of HII's control, HII's actual results and performance may differ materially from the results expressed or implied by such forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Other important risk factors that may affect HII's business, results of operations and financial position are discussed in its most recently filed Annual Report on Form 10-K, recent Quarterly Reports on Form 10-Q, recent Current Reports on Form 8-K and in other Securities and Exchange Commission filings. Unless otherwise required by law, HII also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. However, readers should review carefully reports and documents that HII files periodically with the Securities and Exchange Commission.
Contact:
Matthew Flemming, HII Technologies, Inc. +1-713-821-3157.
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
More: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: HII Technologies, Inc.: one month profile and news distribution effective March 20, 2013 with option to renew: two thousand per month
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Mining Stock Alert: In a New Audio at SmallCapVoice.com, Ronald Mann, CEO of DNA Precious Metals, Inc. (OCTQB: DNAP), Discusses Recent News and Events for the Company

AUSTIN, Texas - November 5, 2013 (Investorideas.com Mining stocks newswire) SmallCapVoice.com, Inc. announced today that a new audio interview with DNA Precious Metals, Inc. (DNAP) is now available. The interview can be heard at http://smallcapvoice.com

Ron Mann, CEO of DNA Precious Metals, Inc., called into SmallCapVoice.com to go over the recent news and projects for the Company. This interview provides Mr. Mann's personal insight into the recent news regarding DNAP presentation at the 2013 Silver Summit conference in Spokane, Washington, the recent announcement that DNAP has signed a Binding Agreement to acquire an undivided one hundred (100%) interest for all of the Montauban Mine Property assets located in Notre-Dame-de-Montauban, Quebec, Canada, and much more.
About DNA Precious Metals, Inc.
DNA Precious Metals, Inc. is focused on near term production of the Montauban tailings mine in the Province of Quebec, Canada with an aggressive search for economic production assets. The company trades on the OTCQB market in the United States under the stock symbol DNAP. For more information, please go to   www.DNAPreciousMetals.com .
For more information, visit http://www.dnapreciousmetals.com.
Forward Looking Disclaimer: This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at http://www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts' expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company's future stock price, its revenues or results of operations.
CONTACT INFORMATION
Ronald Mann, CEO
DNA Precious Metals Inc.
ronald.mann1@dnapreciousmetals.com
Twitter: www.twitter/dnametals
Facebook: www.facebook.com/dnametals
INVESTOR RELATIONS
Stuart T. Smith, CEO
SmallCapVoice.Com, Inc.
ssmith@smallcapvoice.com
Tel: +1-(512)-267-2430
Skype: SmallCapVoice.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Investorideas is compensated by DNAP for news and content publication and syndication ( October 2013 - five thousand for one month of news distribution on Investor ideas news wire ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Biometric Stock Alert: Nxt-ID, Inc. (OTCQB:NXTD) Announces Release of Biometric Mobile App Ahead of Schedule

SHELTON, CT - November 4, 2013 (Investorideas.com biometrics/ defense stocks newswire) NXT-ID Inc. (OTCQB: NXTD), a biometrics company focused on the growing mobile commerce market, announced today that it has successfully developed its Voicematch™ algorithm for mobile platforms. Originally scheduled for full release in Q3 2014, progress on the development of Voicematch™ Mobile App technology has exceeded original expectations, prompting NXT-ID to release the product earlier than anticipated.

Voicematch™ is a new method of recognizing both speakers and specific words providing innovative multi-factor recognition that is efficient enough to run on low-power devices.
"We are extremely excited to enable speaker recognition as a multi-factor authentication method for mobile and wearable devices, as speaking is a very natural way to be authenticated," says Gino Pereira, CEO of NXT-ID. "Apple has validated the use of biometrics on mobile platforms by the use of fingerprint scanners on its latest products. Voice authentication is the next step forward."
Voicematch™ is a key multi-factor biometric of NXT-ID's MobileBio™ mobile and wearable identity technologies that bring full control and protection of private data to authenticated users. It is multi-platform, meaning it will run on mobile platforms such as Android and iOS, as well as laptops and desktops. It will also be one of the multi-factor authentication methods for NXT-ID's ultra-low power electronic wallet -- the Wocket™.
"What's amazing is the accuracy that we are achieving with this new voice recognition algorithm with very low power requirements," says David Tunnell, CTO of NXT-ID. "The efficiencies of this product makes biometric authentication possible for a number of mobile and wearable applications where low-power is paramount."
The Company's target market includes smartphone manufacturers and app providers that use personal and sensitive information in their applications.
Details of this innovative technology are forthcoming via an imminent patent application.
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms. NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Corporate info: info@nxt-id.com
Investor Relations
ProActive Capital Group
Direct: 646 863 6341
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: this release was compensated for by NXTD as part of a monthly service for news publication and distribution and content marketing. (five thousand per month plus 144 shares)
More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Note: Grand Opening of Exosome Sciences Subsidiary on November 12th at 6:30pm Eastern

SAN DIEGO - November 4, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

As a follow-up to my October 15th note, I am pleased to inform shareholders and other interested parties that we will host a grand opening event for our Exosome Sciences, Inc. (ESI) subsidiary on November 12th at 6:30pm eastern. Individuals that wish to attend the event should RSVP by email to Chris Wetzel (ESI Director of Operations) by the end of the business day on Friday November 8th. Chris's email address is: cwetzel@exosomesciences.com. The event will be held at our new ESI lab located within the Princeton Research Center. The address is 11 Deer Park Drive, Suite 103, Monmouth Junction, NJ 08852. Directions can be accessed online at: www.princetoncorporateplaza.com/contact.html.
We established Exosome Sciences as a stand-alone subsidiary to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. We believe exosomes are an optimal diagnostic target as diseased cells release them into bodily fluids such as urine and blood where they can be accessed. Our ESI subsidiary is developing non-invasive liquid biopsies based on the knowledge that these exosomes transport disease-origin markers underlying a wide-range of disease conditions. In regards to ESI's leadership, we have retained two of the best-known thought leaders in the exosome industry. Dr. Douglas Taylor as ESI's Chief Scientific Officer and Dr. Cicek Gercel-Taylor as ESI's Clinical Research Director. In closing, I look forward to introducing our ESI team on the 12th.
About Dr. Douglas Taylor
Dr. Taylor discovered and pioneered the field of exosome biology and their role in intercellular communication and immune regulation. He has been in the Department of Obstetrics, Gynecology and Women's Health at the University of Louisville School of Medicine since 1992. Dr. Taylor published the initial article describing circulating tumor exosomes/microvesicles in 1979 (Anal. Biochem. 98:53-59, 1979). The research in his laboratory has primarily focused on the release and consequences of exosomes from gynecologic cancer and lung tumors. Over the past 30+ years, Dr Taylor has pioneered the isolation and characterization of circulating tumor-derived exosomes. His work has focused on characterization of circulating exosomes released by tumor cells for their role in immune regulation and induction of a pro-inflammatory tumor microenvironment. His work has demonstrated that the presence of specific circulating exosomal components have potential use as biomarkers for cancer patients.
About Dr. Gercel-Taylor
Dr. Cicek Gercel-Taylor has been a pioneer in the field of exosome biology and in defining their nucleic acid and protein cargoes. She previously has worked at the Department of Obstetrics, Gynecology and Women's Health at the University of Louisville School of Medicine since 1992, and also is the Resident Research Coordinator. Her main research interest is in gynecological cancers, where she investigates the consequences of exosomes on genetic and epigenetic alterations induced in normal host target cells. She has explored the role of endogenous and exogenous hormones in modulating exosomal cargoes and the resulting effects on pathologic processes. A significant part of these investigations includes the identification and characterization of clinically relevant biomarkers, specifically proteomic and miRNA content of pathology-derived exosomes.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar